Drug Trial Radar · NCT04294810
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
620
Actual
Start
Mar 4, 2020
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.
Conditions
- Non-Small Cell Lung Cancer
Interventions
AtezolizumabDrug
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
TiragolumabDrug
Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Matching PlaceboDrug
Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
- China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PASTime frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
- Global Cohort: Overall Survival (OS) in the PASTime frame: From randomization to death from any cause (up to approximately 54.7 months)
- China Cohort: OS in the PASTime frame: From randomization to death from any cause (up to approximately 49.1 months)
- Global Cohort: Number of Participants With Adverse Events (AEs)Time frame: Up to 65.1 months
- China Cohort: Number of Participants With AEsTime frame: Up to 49.3 months
- Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading ScaleTime frame: Up to 65.1 months
- China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading ScaleTime frame: Up to 49.3 months
Locations
132 sites in 23 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Center - Denver
Denver, Colorado
Yale Cancer Center
New Haven, Connecticut
SCRI Florida Cancer Specialists North
St. Petersburg, Florida
SCRI Florida Cancer Specialists PAN
Tallahassee, Florida
US oncology research at Minnesota Oncology
Saint Paul, Minnesota
SCRI Oncology Partners
Nashville, Tennessee
Virginia Cancer Specialists (Fairfax) - USOR
Fairfax, Virginia
Onc & Hem Assoc SW Virginia
Salem, Virginia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Austin Hospital Olivia Newton John Cancer Centre
Heidelberg, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Ordensklinikum Linz Elisabethinen
Linz, Austria
Klinik Penzing
Vienna, Austria
Krankenhaus Nord - Klinik Floridsdorf
Vienna, Austria
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Beijing Cancer Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
West China Hospital, Sichuan University
Chengdu, China
Chongqing Cancer Hospital
Chongqing, China
Fujian Cancer Hospital
Fuzhou, China
Hainan General Hospital
Haikou, China
Sir Run Run Shaw Hospital Zhejiang University
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Jinan Central Hospital
Jinan, China
Meizhou People's Hospital
Meizhou, China
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, China
Nantong Tumor Hospital
Nantong, China
Zhongshan Hospital Fudan University
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, China
Zhejiang Cancer Hospital
Zhejiang, China
Krankenhaus Nordwest
Frankfurt, Germany
LungenClinic Großhansdorf GmbH
Großhansdorf, Germany
Krankenhaus Martha-Maria Halle-Doelau gGmbH
Halle, Germany
Fachklinik für Lungenerkrankungen
Immenhausen, Germany
SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
Löwenstein, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie
Münster, Germany
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.